Denali Therapeutics Inc. DNLI
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 154.98% | 0.70% | 0.08% | -1.30% | -2.24% |
| Total Depreciation and Amortization | 0.16% | 19.22% | -0.56% | -2.07% | -2.38% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -756.59% | 22.44% | -1.11% | -3.42% | 1.79% |
| Change in Net Operating Assets | -6,229.32% | 101.39% | -648.17% | 180.63% | -126.71% |
| Cash from Operations | -21.07% | 26.07% | -33.15% | 8.16% | -42.50% |
| Capital Expenditure | -25.47% | 67.36% | -61.81% | -210.60% | 132.21% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -71.20% | -206.55% | 334.80% | -60.51% | -65.20% |
| Cash from Investing | 115.56% | -210.18% | 354.83% | -64.09% | -63.38% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -4.76% | -23.53% | -6.25% | 98.82% | 44.08% |
| Issuance of Common Stock | -82.28% | -21.28% | -97.93% | 157,785.59% | -85.63% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -100.00% | 127.46% | -- | -- |
| Cash from Financing | -82.70% | -93.16% | 14.01% | 24,795.76% | -147.94% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 46.98% | -202.08% | 59.40% | 327.62% | -159.63% |